PAREXEL Named to the Forbes America’s Best Employers List for Second Consecutive Year
June 26 2017 - 09:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced
that for the second year in a row, Forbes has named the Company to
its America’s “Best Employers” list. The list recognizes the top
300 midsized employers and top 500 large employers. Results are
based on anonymous survey responses from 30,000 U.S. employees,
with the most weighted factor being how likely they were to
recommend their organizations to others.
“Receiving this recognition for the second consecutive year is a
testament to our efforts to advance investments in developing our
people, and we are pleased to see that reflected in strong feedback
from employees,” said Michelle Graham, Senior Vice President and
Chief Human Resources Officer, PAREXEL. “We strive to attract,
develop and retain top talent at PAREXEL to best serve our clients
in bringing new, life-saving treatments to patients around the
globe.”
PAREXEL is committed to investing in its people and fostering an
environment in which employees are engaged and empowered to do
their best work in an effort to deliver for clients. To further
this goal, PAREXEL provides best-in-class training programs and
professional growth opportunities, as well as flexible work
options. Recently, PAREXEL’s training program was recognized in
Training magazine’s “Training Top 125” for developing creative and
effective learning and development initiatives for its global
workforce.
About the Forbes America’s Best Employers List
MethodologyNow in its third year, the Forbes ranking of
America’s Best Employers is drawn from an online survey of more
than 30,000 employees at companies with at least 1,000 people in
their U.S. operations. Participation in the survey was voluntary,
and respondents were recruited from thousands of sources to
maximize reach and representation. The mix of respondents (gender,
age, region, and ethnicity) in the sample represents American
employees. Each employee surveyed was asked to rank both his own
employer and other employers in the same industry sector. Employees
were also asked how likely they were to recommend their
organization to friends or family; this was the most important
factor in determining a company’s ranking on the list.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology, and
medical device industries. Committed to providing solutions that
expedite time-to-market and peak-market penetration, PAREXEL has
developed significant expertise across the development and
commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical trials management,
and reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626005076/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2023 to Mar 2024